Company: DAWN
Filing Date: 2025-03-06
Form Type: 10-K/A
Source: 0000950170-25-034878
Chunk: 51

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K/A
Chunk 51
---
     |                    |  1,774,287 |     |      |    984,920 |
| Shares committed under ESPP |     |                    |    113,296 |     |      |    104,700 |
| Total                       |     |                    | 14,097,299 |     |      | 11,905,557 |

<div align='center'>F-32</div>

11. Income Taxes

All pre-tax losses have been incurred in the United States. The total tax expense is comprised of current U.S. federal income tax expense of approximately $1.9million and current U.S. state and local income tax expense of approximately $5.2million.

The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows:

|                               |     | Year Ended December 31, |  2024 |    |     |     |  2023 |    |     |     |  2022 |    |
|:------------------------------|:----|:------------------------|------:|:---|:----|:----|------:|:---|:----|:----|------:|:---|
| Statutory rate                |     |                         |  21.0 | %  |     |     |  21.0 | %  |     |     |  21.0 | %  |
| State tax                     |     |                         |  28.9 | %  |     |     |   0.5 | %  |     |     |   0.6 | %  |
| Permanent differences         |     |                         |  (0.1 | )% |     |     |  (0.3 | )% |     |     |     — |    |
| Credits                       |     |                         |  19.3 | %  |     |     |   2.0 | %  |     |     |   1.7 | %  |
| Change in valuation allowance |     |                         | (68.5 | )% |     |     | (21.5 | )% |     |     | (22.6 | )% |
| Share-based compensation      |     |                         |  (4.8 | )% |     |     |  (1.7 | )% |     |     |  (0.7 | )% |
| Unc